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a  b  s  t  r  a  c t
Fabry disease is a rare X-linked lysosomal storage disorder of glycosphingolipids, caused by
the  partial or complete deﬁciency of the lysosomal enzyme alpha-galactosidase A (a-Gal A).
The  missense mutation pN215S usually causes a milder form of the disease with isolated
cardiac  involvement. We  report a case of a male Fabry patient with the pN215S mutation
and  a generalized disease. He suffered a relapse in proteinuria which responded to increased
doses  of the administered recombinant enzyme. Individualization of enzyme replacement
therapy must be considered in selected cases characterized by clinical deterioration.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open  access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Control  de  la  proteinuria  con  aumento  de  dosis  de  agalsidasa  alfa  en  un
paciente  con  enfermedad  de  Fabry  y  expresión  de  genotipo-fenotipo
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r  e  s  u  m  e  n
La enfermedad de Fabry es un trastorno hereditario raro ligado al cromosoma X, que se
caracteriza por un almacenamiento lisosómico de glucoesﬁngolípidos causado por una deﬁ-
ciencia parcial o completa de la enzima lisosómica -galactosidasa A (a-Gal A). La mutación
sin  sentido pN215S suele provocar una forma más leve de la enfermedad, con afectación
cardíaca  aislada. Se describe un caso de enfermedad de Fabry en un paciente varón con
la  mutación pN215S y enfermedad generalizada. El paciente presentó una recidiva de la
proteinuria que respondió al aumento de dosis de la enzima recombinante administrada.
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Debe considerarse la posible conveniencia de una individualización de la terapia sustitutiva
enzimática  en casos seleccionados que presenten deterioro clínico.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo  Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Fabry disease is a rare genetic lysosomal storage disorder of
glycosphingolipids with X-linked transmission and an esti-
mated incidence of 1:40,000–1:117,000 live male births.1 Partial
or complete deﬁciency of the enzyme alpha-galactosidase
A (a-Gal A) results in altered metabolism and progressive
lysosomal accumulation of the substrate (mostly globotriao-
sylceramide, Gb3).2 The responsible gene is located on the long
arm of the chromosome X (Xq22). More  than 600 mutations
have been identiﬁed with variable phenotypical expression.3
Clinically we  distinguish the classical form and two
variants, cardiac and renal. In the classical form clinical
manifestations appear during childhood or early adolescence
including acroparesthesias, angiokeratomas and corneal
opacities.4 Progressive accumulation of Gb3 in the kidneys,
heart and central nervous system lead to renal failure,
hypertrophic cardiomyopathy and cerebral vascular accidents
limiting life expectancy. The cardiac variant of the disease is
associated with residual alpha-galactosidase A activity (>1%),
appearing later in life. The patients suffer from left ven-
tricular hypertrophy and hypertrophic cardiomyopathy with
decreased systolic function. Other cardiac manifestations
include valvular disease with thickened valves (especially left-
sided) and regurgitation, myocardial ischemia, arrhythmias
(frequently supraventricular) and ECG changes such as voltage
criteria for LVH and repolarization abnormalities, shortened
P-R, A-V block or bundle branch block.5 The clinical picture
is dominated by the aforementioned cardiac manifestations,
while the classical signs and symptoms are usually absent.
Some patients may present a degree of proteinuria without
severe renal failure.6
Advances in the application of molecular genetic tech-
niques have enabled the development of directed protein
therapies for lysosomal storage diseases. In case of Fabry
disease two formulations of recombinanat enzyme are cur-
rently available. Agalsidase-alfa (Replagal®, Shire) is derived
from human skin ﬁbroblasts and is administered intra-
venously at dose of 0.2 mg/kg every 14 days. Accordingly,
agalsidase-beta (Fabrazyme®, Genzyme) is produced by Chi-
nese Hamster ovary cell line and is given intravenously at dose
of 1 mg/kg every 14 days.
We  present the case of a male Fabry patient who was diag-
nosed with the missense mutation pN215S who in addition
to cardiac involvement also presented serious extracardiac
clinical manifestations. In our case, twenty months after the
initiation of agalsidase-alfa in the conventional dose, an incre-
ment of proteinuria and left ventricular mass were noted.
Switching the patient to double dose of the enzyme led to
reduction of proteinuria and reestablishment of the cardiac
indexes.
Case  report
A 41-year old male was presented in the Renal Outpatient
Clinic with proteinuria of 0.5 g/d and left ventricular hypertro-
phy. His renal function was normal (eGFR 122 ml/min/1.73 m2).
The patient underwent a renal biopsy which showed glomeruli
with enlarged podocytes displaying abundant ﬁne, granular
and lucent protoplasm. Some tubular epithelial cells had a
vacuolated and lucent cytoplasm or atrophy while mild inter-
stitial ﬁbrosis was also present (<10%). Immunoﬂuorescence
showed IgM deposition in mesangium of two glomeruli with
granular distribution. Histological ﬁndings in association
with the clinical manifestations led to further investiga-
tion toward diagnosis of Fabry disease. Indeed, low activity
of -Gal A in plasma and in leucocytes (0.3 nmoles/ml/h
and 1.5 nmoles/mg protein/h, respectively) led to the afore-
mentioned diagnosis. The subsequent familiar genetic
investigation revealed that both he and his mother, a 70-year
old female, had the pN215S missense mutation, correspond-
ing to adenine replacement in the position 10135 with guanine
(10135A → G).
Monitoring of the patients, performed twice a year,
included biochemical exams of renal function and 24-h mea-
surement of proteinuria, cardiac ultrasound and pro-BNP
levels, plasma and urine levels of Gb3 as well as the titer
of the anti-agalsidase antibodies and brain MRI scan every
other year. The female suffered from left ventricular hyper-
trophy, without renal or CNS involvement. On the contrary,
male patient had a complex phenotype with left ventricular
hypertrophy, proteinuria and CNS lesions. Brain imaging with
MRI scan showed vascular dolichoectasia in the vertebrobasi-
lar junction and punctuated white matter lesions in the frontal
lobe as well as in the basal ganglia.
The male patient was administered agalsidase-alfa
(Replagal®, Shire) in the recommended dose of 0.2 mg/kg/d
every 2 weeks and an ACE inhibitor in the maximum
tolerated dose (ramipril 5 mg  daily). Enzyme replacement ther-
apy began 3 months after the histologic diagnosis.
During the ﬁrst 20 months both renal and cardiac indexes
remained stable and no other relevant event was noticed. At
that point in the male patient a steep increase of protein-
uria (from 560 to 2536 mg/d) as well as an increase in left
ventricular mass (from 412 to 464.5 g) and pro-BNP levels
(from 190 to 266.5 pg/ml) were observed. After measurement of
Gb3 levels in plasma (5.86 nmol/ml) and exclusion of develop-
ment of neutralizing anti-agalsidase-a IgG and IgA antibodies
we considered to adapt the therapeutic regimen. Thus we
administered, with the same frequency, double dose of
enzyme (0.4 mg/kg/d). Seven months later, proteinuria
decreased from 2536 to 986 mg/d and the indexes of cardiac
size were reestablished. Accordingly plasmatic levels of Gb3
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Fig. 1 – Graphic albuminuria.
were 5.11 nmol/ml. Targeting to verify this apparent dose-
dependent effect, the conventional dose was re-administered
and one month later proteinuria relapsed (2886 mg/d) (Fig. 1).
Therefore the patient switched to the double dose. After
24 months, he still presents albuminuria of 1053 mg/d and
stable cardiac size and function (LV mass = 414.8 g, pro-
BNP = 166.5 pg/ml). Repeated brain MRI  scan showed no
evolution of the lesions.
Discussion
Although, all types of renal cells as well as the endothe-
lium of the blood vessels may be affected, podocyte injury
is central in the pathophysiology of Fabry nephropathy.7 Pro-
gressive damage of the glomerular ﬁltration barrier leads
to the early appearance of the albumin in the urine sub
form of microalbuminuria.8 Non-nephrotic range proteinuria
developes frequently during the 3rd decade of life and renal
failure in the 4th–5th decade, progressing to end stage renal
disease after 1–13 years.9 In Fabry patients proteinuria is
an independent factor of worsening of renal function and
progression to ESRD. Retrospective studies of ERT-untreated
cohorts showed that the level of proteinuria was inde-
pendently associated with the rate of decline of eGFR.10,11
Administration of ERT improves renal histopathology lead-
ing to signiﬁcant clearance of the Gb3 deposits from the
renal interstitial vascular endothelium and other glomerular
cells.12,13 Clinically, the maximal renal protection is achieved
when ERT is given before the development or in an early stage
of CKD (eGFR >60 ml/min/1.73 m2 or proteinuria <1 g/d).13–15
On the contrary, the effectiveness of ERT is much less consis-
tent in face of an advanced renal failure and irreversible organ
damage.16,17 Thus proteinuria must be a major therapeutic
target in Fabry nephropathy.
Our patient was diagnosed with the missense mutation
pN215S (transition of A → G in codon 215 of exon 5 with sub-
stitution of an asparagine by a serine). This genetic defect
usually leads to a late-onset phenotype, dominated by car-
diac manifestations.18,19 However, in this case the phenotypic
expression was different with renal and CNS involvement
besides cardiac hypertrophy. To our knowledge this is the
ﬁrst case of a Fabry patient with the pN215S mutation and
extracardiac clinical manifestations.
Although the patient had normal renal function, control
of proteinuria to levels <1 g/d was necessary. Low blood pres-
sure (100/65 mmHg) prevented us from further titration of
the ACE inhibitor. Thus, we  decided to increase the admin-
istered enzyme by doubling the recommended dose. This
choice was based upon previous in vitro observation that
administration of recombinant human galactosidase is
associated with increased tissue enzymatic activity in a dose-
dependent manner.20 During the next seven months we
observed a gradual decrease in proteinuria levels as well
as in left ventricular mass. This dose-dependent effect was
veriﬁed by switching the patient to the conventional dose
of agalsidase-alfa for one month period, after which a re-
deterioration of proteinuria was noticed. Therefore the patient
switched to the double dose regaining the prior albuminuria
levels and stable cardiac size and function. The ﬁndings sus-
tained 24 months later.
Although long-term administration of enzyme replace-
ment therapy (ERT) appears safe and effective leading to
clinical stabilization,21 there are still controversies regard-
ing the appropriate ERT regimen in case of progressive
clinical deterioration. A dose-dependent effect has been
observed in such a case with advanced nephropathy.22 In
an open-label, prospective clinical trial of 11 male patients
with advanced Fabry nephropathy (mean baseline eGFR
53.7 ± 6.3 ml/min/1.73 m2) and rapid annual decline of eGFR
(−8 ± 0.8 ml/min/1.73 m2), switching agalsidase-alfa regimen
from the conventional biweekly dosing to weekly infusions
of 0.2 mg/kg for a 24-month period slowed eGFR’s decline
(−3.3 ± 1.4 ml/min/1.73 m2).23
The question of the optimal ERT dose has also been tested
by Vedder et al. who administered 3 different ERT regimens
in 52 Fabry patients (0.2 mg/kg agalsidase-alfa, 0.2 mg/kg or
1 mg/kg agalsidase beta). After 12 months of follow-up the
patients who received 1 mg/kg of agalsidase-beta presented
decreased levels of urinary Gb3 levels, independent of their
anti-agalsidase antibody status. Moreover, a reduction of left
ventricular mass was observed.24 However, the results of a
comparative trial between the two products administered in
34 patients at the same dose (0.2 mg/kg biweekly), showed no
difference regarding reduction of left ventricular mass after 12
and 24 months of treatment. There was also no difference con-
cerning other clinical or laboratory parameters (eGFR, pain,
plasma and urinary Gb3 levels, anti-agalsidase antibodies) or
treatment failure between the two treatment groups.25 In our
case administration of double of the recommended dose of
agalsidase-alfa, besides better compliance, was followed by a
signiﬁcant decrement of proteinuria as well as decrease of the
left ventricular mass.
In conclusion, individualization of ERT should be consi-
dered in selected cases of Fabry disease when conventional
dosing and symptomatic treatment are not effective to con-
trol clinical manifestations. However, additional investigation
is required in order to evaluate cost–effectiveness of such an
intervention.
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